The ability to alter proteins to refine control over binding affinity and specificity can create tailored therapeutics with reduced side effects, highly sensitive diagnostic tools, efficient ...

All the ERBB receptors except ERBB2 have known ligands, and all except ERBB3 have relatively active kinase domains. Although ERBB2 is minimally active in ligand binding, it is the preferred ...

Researchers from Southwest Jiaotong University published the discovery of novel high affinity peptides against the protein of human DNA binding domain of FOXM1 (FOXM1-DBD) to be developed for the ...